Reset Therapeutics
South San Francisco, US · Delaware corporation · 2 known investors
Founders & leadership
SK
Shuichi KurosakiExecutive
PH
Paul HumphriesExecutive
RB
Ross BersotExecutive
SK
Steve KayNamed on SEC filing
PS
Peter SchultzNamed on SEC filing
Board
FB
Frederick B CravesBoard director
HH
Hoyoung HuhBoard director
Investors · 2
.jpeg){kind=logo}
Reported raises · per SEC filings
Form D private placements$47.9M disclosed across 5 rounds · 2014–2022
▶$1.6MraisedJan 2022 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedJan 2022 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Blair JacksonDirector
- Steve KayDirector
- Frederick B CravesDirector
- Shu KurosakiExecutive Officer
- Glenn BatchelderExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedOct 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$6MraisedOct 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick B CravesDirector
- Steve KayDirector
- Shuichi KurosakiExecutive Officer
- Glenn BatchelderExecutive Officer, Director
- Blair JacksonDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJun 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedJun 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Blair JacksonDirector
- Glenn BatchelderDirector
- Frederick B CravesDirector
- Steve KayDirector
- Shuichi KurosakiExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$29.7MraisedFeb 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$29.7MraisedFeb 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Hoyoung HuhDirector
- Ross BersotExecutive Officer, Director
- Shuichi KurosakiExecutive Officer
- Frederick B CravesDirector
- Steve KayDirector
- Peter SchultzDirector
- Paul HumphriesExecutive Officer
- Offering amount
- $47.2M
- Amount sold
- $29.7M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.1MraisedOct 2015 · 2 investors · PharmaceuticalsRule 506(b)
▶$9.1MraisedOct 2015 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shuichi KurosakiExecutive Officer
- Paul HumphriesExecutive Officer
- Steve KayDirector
- Frederick B CravesDirector
- Hoyoung HuhDirector
- Peter SchultzDirector
- Ross BersotExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $9.1M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Reset Therapeutics's investors?
- Reset Therapeutics's investors include Bay City Capital GF Xinde International Life Sciences USD, Goldcrest Capital.
- How much funding has Reset Therapeutics raised?
- Reset Therapeutics has disclosed $47.9M raised across 5 rounds.
- Where is Reset Therapeutics headquartered?
- Reset Therapeutics is headquartered in South San Francisco, US.